Prathima Nandivada1, Gillian L Fell1, Paul D Mitchell2, Alexis K Potemkin1, Alison A O'Loughlin1, Kathleen M Gura3, Mark Puder1. 1. 1 Vascular Biology Program and Department of Surgery, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 2. 2 Clinical Research Center, Boston Children's Hospital, Boston, Massachusetts, USA. 3. 3 Department of Pharmacy, Boston Children's Hospital, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Fish oil lipid emulsion (FOLE) and multidisciplinary care for infants with intestinal failure (IF) have been associated with reduced morbidity and mortality due to IF-associated liver disease (IFALD). With increased survival, a greater proportion of infants with IF are now able to remain on parenteral nutrition (PN) in the long term. The purpose of this study was to examine outcomes in children with IFALD who have required long-term PN and FOLE therapy due to chronic IF. MATERIALS AND METHODS: A review of prospectively collected data was performed for children with IFALD who required at least 3 years of PN and FOLE therapy due to chronic IF. Outcomes examined include the incidence of death, transplantation, and essential fatty acid deficiency (EFAD), as well as growth parameters and the biochemical markers of liver disease. RESULTS: Of 215 patients with IFALD treated from 2004-2015, 30 required PN and FOLE therapy for at least 3 years (median, 4.6 years). To date, no patients have died, required transplantation, or developed EFAD. Biochemical markers of liver disease normalized within the first year of therapy with no recurrent elevations in the long term. Weight-for age and length-for-age z scores improved and PN dependence decreased in the first year of therapy, with a stable rate of growth in the long term. CONCLUSIONS: Children with IFALD who required long-term PN and FOLE for chronic IF had no mortality, need for transplantation, EFAD, or recurrence of liver disease in the long term, allowing for continued intestinal rehabilitation.
BACKGROUND: Fish oil lipid emulsion (FOLE) and multidisciplinary care for infants with intestinal failure (IF) have been associated with reduced morbidity and mortality due to IF-associated liver disease (IFALD). With increased survival, a greater proportion of infants with IF are now able to remain on parenteral nutrition (PN) in the long term. The purpose of this study was to examine outcomes in children with IFALD who have required long-term PN and FOLE therapy due to chronic IF. MATERIALS AND METHODS: A review of prospectively collected data was performed for children with IFALD who required at least 3 years of PN and FOLE therapy due to chronic IF. Outcomes examined include the incidence of death, transplantation, and essential fatty acid deficiency (EFAD), as well as growth parameters and the biochemical markers of liver disease. RESULTS: Of 215 patients with IFALD treated from 2004-2015, 30 required PN and FOLE therapy for at least 3 years (median, 4.6 years). To date, no patients have died, required transplantation, or developed EFAD. Biochemical markers of liver disease normalized within the first year of therapy with no recurrent elevations in the long term. Weight-for age and length-for-age z scores improved and PN dependence decreased in the first year of therapy, with a stable rate of growth in the long term. CONCLUSIONS:Children with IFALD who required long-term PN and FOLE for chronic IF had no mortality, need for transplantation, EFAD, or recurrence of liver disease in the long term, allowing for continued intestinal rehabilitation.
Entities:
Keywords:
IFALD; PNALD; fish oil lipid emulsion; intestinal failure-associated liver disease; long term; parenteral nutrition; parenteral nutrition-associated liver disease
Authors: Lee Call; Tiffany Molina; Barbara Stoll; Greg Guthrie; Shaji Chacko; Jogchum Plat; Jason Robinson; Sen Lin; Caitlin Vonderohe; Mahmoud Mohammad; Dennis Kunichoff; Stephanie Cruz; Patricio Lau; Muralidhar Premkumar; Jon Nielsen; Zhengfeng Fang; Oluyinka Olutoye; Thomas Thymann; Robert Britton; Per Sangild; Douglas Burrin Journal: J Lipid Res Date: 2020-04-29 Impact factor: 5.922
Authors: Lorenzo Anez-Bustillos; Duy T Dao; Gillian L Fell; Meredith A Baker; Kathleen M Gura; Bruce R Bistrian; Mark Puder Journal: Clin Nutr Date: 2017-07-08 Impact factor: 7.324
Authors: Peter J H Jones; Maryam Shamloo; Dylan S MacKay; Todd C Rideout; Semone B Myrie; Jogchum Plat; Jean-Baptiste Roullet; David J Baer; Kara L Calkins; Harry R Davis; P Barton Duell; Henry Ginsberg; Helena Gylling; David Jenkins; Dieter Lütjohann; Mohammad Moghadasian; Robert A Moreau; David Mymin; Richard E Ostlund; Rouyanne T Ras; Javier Ochoa Reparaz; Elke A Trautwein; Stephen Turley; Tim Vanmierlo; Oliver Weingärtner Journal: Nutr Rev Date: 2018-10-01 Impact factor: 7.110
Authors: Caroline Wang; Robert S Venick; Stephen B Shew; James C Y Dunn; Laurie Reyen; Rong Gou; Kara L Calkins Journal: JPEN J Parenter Enteral Nutr Date: 2018-11-08 Impact factor: 4.016
Authors: Lorenzo Anez-Bustillos; Duy T Dao; Meredith A Baker; Gillian L Fell; Mark Puder; Kathleen M Gura Journal: Nutr Clin Pract Date: 2016-08-16 Impact factor: 3.080
Authors: Margaret L Ong; Robert S Venick; Stephen B Shew; James C Y Dunn; Laurie Reyen; Tristan Grogan; Kara L Calkins Journal: JPEN J Parenter Enteral Nutr Date: 2019-03-22 Impact factor: 4.016